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INTRODUCTION
In response to a request from the National Marrow
Donor Program and the International Bone Marrow Trans-
plant Registry (IBMTR), a workshop was convened at the
annual meeting of the American Society of Blood and Mar-
row Transplantation (ABMTR) and the IBMTR/ABMTR
(2001 Tandem BMT Meetings) to discuss chimerism analy-
sis after allogeneic transplantation. This request was stimu-
lated by the desire to establish a rational and reasonably
uniform approach to the routine measurement of lympho-
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ABSTRACT
Approaches to the measurement of lymphohematopoietic chimerism have evolved from laboratory research to
important clinical tools. However, there has been no logical, consistent, and uniform set of recommendations for
the measurement of chimerism in clinical transplantation. The National Marrow Donor Program and the Interna-
tional Bone Marrow Transplant Registry (IBMTR) sponsored a workshop to discuss the use of chimerism analysis
after allogeneic transplantation. The workshop was organized in an effort to make reasonable recommendations
regarding laboratory techniques, the types of specimens to be studied, and the frequency of analysis. The panel rec-
ommended the following guidelines: 
1. Chimerism analysis should use sensitive, informative techniques. At present, short tandem repeats (STR) or vari-
able number tandem repeats (VNTR) analysis is the approach most likely to give reproducible informative data. 
2. Peripheral blood cells are generally more useful than bone marrow cells for chimerism analysis. 
3. Lineage-specific chimerism should be considered the assay of choice in the setting of nonmyeloablative and
reduced-intensity conditioning. 
4. The use of T-cell depletion, nonmyeloablative or reduced-intensity conditioning, or novel graft-versus-host dis-
ease (GVHD) prophylactic regimens warrants chimerism analysis at 1, 3, 6, and 12 months, because interven-
tions such as donor lymphocyte infusions may depend on chimerism status. 
5. In nonmyeloablative transplantation, the early patterns of chimerism may predict either GVHD or graft loss.
Therefore, more frequent (every 2-4 weeks) peripheral blood analysis may be warranted. 
6. For nonmalignant disorders, chimerism generally should be measured 1, 2, and 3 months after transplantation.
Interventions to enhance donor engraftment must be considered on a disease-specific basis in relation to con-
current GVHD and, ultimately, clinical rationale.
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hematopoietic chimerism that could be standardized across
treatment centers. Such a system would allow the retrospec-
tive analysis of chimerism data by each registry. An expert
panel was convened and the workshop was organized in an
effort to make reasonable recommendations regarding labo-
ratory techniques, the types of specimens to be studied, and
the frequency of analysis. Because of the lack of published
(and unpublished) data from systematic evaluations of this
area, this set of guidelines is not an evidence-based review.
Rather, it represents a consensus view of the authors with
input from persons who participated in the workshop.
Definitions
The term chimerism refers to the presence of lympho-
hematopoietic cells of nonhost origin (Table 1). These
cells could be derived incidentally from a fetal-maternal
transfusion or a blood transfusion or purposefully after
hematopoietic stem cell transplantation (HSCT). Full or
complete chimerism generally refers to complete replace-
ment of host by donor lymphohematopoiesis. Mixed
chimerism indicates the presence of both donor and recip-
ient cells within a given cellular compartment, eg, lym-
phocytes. The term split chimerism may be used when
one or more compartment is derived wholly from the
donor. It is recommended that in describing cases of
mixed chimerism the author specify whether the
chimerism was detected in whole blood or whether it is
lineage specific. In the case of split chimerism, the origin
of the lineages studied should be specified. Such terms as
monolineage, bilineage, etc, should be avoided in favor of
specification of the cell  l ines involved. The term
microchimerism has been used to indicate the presence of
donor cells that are detectable only with very sensitive
techniques. This entity has been described after organ
transplantation [1] and in women with systemic sclerosis
in whom small numbers of fetus-derived cells can be
detected [2,3].
Since the advent of HSCT more than 30 years ago, it
has been recognized that determining the degree to which
the donor’s lymphohematopoietic system has either
superceded or come into equilibrium with the host can be
critical to establishing the success of the procedure. More-
over, this determination provides a rational method of
assessing the ability of different conditioning regimens,
graft-versus-host disease (GVHD), prophylactic regimens,
and cellular therapy to promote engraftment and graft-
versus-leukemia (GVL) activity. We have learned that these
issues are particularly important in patients who receive
T-cell–depleted or nonmyeloablative transplants, in which
GVL effects may depend on achieving a substantial degree
of donor T-cell chimerism. On the other hand, there may be
situations in which mixed chimerism may be preferable to
full donor chimerism in settings in which full replacement
of host lymphohematopoiesis is not important. There may
be immunologic benefits to establishing a mixed chimeric
state in such diverse situations as organ transplantation, con-
genital disorders of metabolism, and immunotherapy of
solid tumors.
Techniques for Assessment of Chimerism
Very early HSCT studies recognized the importance of
establishing chimerism [4], but early investigators had to
rely on techniques such as red blood cell phenotyping,
immunoglobulin isotype analysis, and cytogenetics to assess
the chimeric state [5-9]. Limitations of these techniques
include limited degrees of polymorphism, poor sensitivity,
and the requirement for a donor and recipient that are sex
mismatched.
One technique that is of value in sex-mismatched trans-
plantation is ﬂuorescent in situ hybridization (FISH) for the
X and Y chromosomes. This technique is now available in
many routine laboratories and is relatively sensitive and
quantitative. Established procedures are commercially avail-
able, making standardization of the methods possible and
ensuring comparable results [10].
The most generally applicable and useful methods to
evaluate chimerism are with DNA techniques using
restriction fragment length polymorphisms (RFLP) [11].
These polymorphisms are neutral variations in DNA
sequence created by either loss or gain of a restriction
enzyme cleavage site or by insertion or deletion of DNA
between restriction sites. The former are generally 2-allele
Table 1. Deﬁnitions
Type of Chimerism Working Definition Comment
Full chimerism 100% Donor cells detected Full chimerism implies complete lymphohematopoietic replacement, 
although most assays are semiquantitative and small numbers of host cells 
may be undetected.
Mixed chimerism Host cells are detected in a The literature often lists 5% or 10% donor cells as a criterion for mixed 
given cellular compartment, chimerism. We have avoided using a number here, because the sensitivity 
eg, lymphocytes of measurement techniques varies, and the implication of chimerism depends
on the disease and the compartment. In general, any reliable detection of
host lymphohematopoietic cells can be considered mixed chimerism.
Split chimerism One or more whole lineage is The details of the split chimerism should be clear, eg, myeloid cells are 100% 
host and one or more whole host and T cells are 100% donor. 
lineage is donor 
Microchimerism <1% Host cells detected Microchimerism has primarily been described using highly sensitive techniques 
in organ transplantation and to evaluate systemic sclerosis. We do not 
recommend its use after allogeneic stem cell transplantation.
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polymorphisms, the latter are often multiallelic if the
insertions or deletions result in the formation of human
minisatellite (variable number of tandem repeats [VNTR])
or microsatellite (short tandem repeats [STR]) regions of
the genome [12]. These loci are inherited in a Mendelian
manner and are useful in assessing chimerism after HSCT.
Important limitations to conventional RFLP analysis after
HSCT are the requirement for at least 106 cells to extract
sufficient DNA for conventional Southern blot analysis
and the lack of sensitivity in detecting minority cell popu-
lations. Introduction of the polymerase chain reaction
(PCR) as a method for rapid amplification of human min-
isatellite and microsatellite regions has provided a powerful
tool for assessing chimerism [13]. By using PCR primers
that flank the minisatellite and microsatellite loci, the
whole allele is amplified and therefore the size of the PCR
product is determined by the length and number of tan-
dem repeats (Figure 1) [14]. In general, analysis of
microsatellites (STR) is simpler than analysis of minisatel-
lites (VNTR). This difference is partly because the repeat
regions of many minisatellites are GC rich and partly
because minisatellite alleles are larger than microsatellite
alleles. Both of these factors make the PCR reaction condi-
tions technically more demanding. The main advantage of
a PCR-based method is enhanced sensitivity, which allows
for detection of minor populations of donor or recipient
cells. In addition, PCR permits analysis from a small num-
ber of cells, thus allowing analysis of engraftment kinetics
before there is morphological evidence of engraftment.
The PCR product can be electrophoresed on an agarose
gel, hybridized with 32P-labeled probes, and autoradi-
ographed (Figure 2), or the PCR can be carried out with
fluorescently labeled primers and the PCR product visual-
ized using the ABI 310 sequencer (Applied Biosystems,
Foster City, CA) (Figure 3). Although the former tech-
nique is generally more sensitive, many labs have now
switched to using fluorescent primer methodologies
because they are faster and avoid the use of radioactivity.
Sensitivity and Quantitation
The sensitivity of chimerism analysis using conventional
PCR methods is limited due to the competitive nature of
the methodology. In general, the sensitivity is between 0.1%
and 5% depending on the allele being tested and whether
Figure 1. Arrowheads represent DNA repeats, either variable number
tandem repeat (VNTR) or short tandem repeat (STR). By using poly-
merase chain reaction (PCR) primers that ﬂank the repeat sequences,
the length of the PCR product will be determined by the number of
repeats in each allele.
Figure 2. Analysis of minisatellite polymerase chain reaction prod-
ucts following agarose gel electrophoresis, hybridization with 32P-
labeled probe, and autoradiography. The figure shows engraftment
kinetics following T-cell–depleted allogeneic transplantation. Donor
engraftment is established within 8 days posttransplantation, but by
day 25 posttransplantation, there is evidence of mixed T-cell
chimerism. PBMC indicates peripheral blood mononuclear cells;
Grans, granulocytes.
Figure 3. Analysis of fluorescent polymerase chain reaction (PCR)
products using the ABI 310 sequencer: lineage-specific chimerism
analyses from 3 separate patients following nonmyeloablative trans-
plantation using microsatellite PCR. The arrow indicates persistence of
recipient cells. Three separate patterns of chimerism are shown. The
left panel shows full donor chimerism following transplantation, the
center panel indicates mixed chimerism in all lineages, and the right
panel shows mixed chimeras in the T-cell lineage alone, similar to that
seen in Figure 2. Stutter peaks can be seen in the donor and recipient
alleles in the left and right panels.
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radioactive or fluorescent detection is being used, as dis-
cussed above [15-18]. High levels of sensitivity can be
obtained by using Y-specific alleles in a sex-mismatched
transplantation (female donor/male recipient), although the
prognostic significance of this low-level chimerism is
unknown. Quantitation is simple using FISH analysis and
can be performed with PCR-based methodologies using
minisatellite and microsatellite alleles [15]. In general, most
PCR-based methods are semiquantitative, although the
degree of quantitation achievable can be increased using
multiplex PCR [16,19]. It is possible that the recent intro-
duction of real-time PCR will allow for greater sensitivity
and more accurate quantitation in the future. Problems with
specificity can arise from “stutter peaks” that result from
“slippery” amplification of repeats during PCR amplifica-
tion [20]. These stutter peaks can be 5% of the size of the
corresponding STR or VNTR and may be particularly
problematic if the informative recipient allele comigrates
with the stutter peak of the donor allele (Figure 3).
Blood Versus Bone Marrow and Unfractionated
Versus Lineage-Specific Analysis?
Whether to use blood or bone marrow analysis and
whether to use unfractionated or lineage-speciﬁc analysis may
appear to be 2 separate questions, but, in essence, they
address the same issue. There are few instances in which bone
marrow chimerism analysis is likely to be more informative
than blood chimerism analysis. One is in the detection of
minimal residual disease in the bone marrow. As discussed
above, chimerism analysis is relatively insensitive—approxi-
mately 1% for detecting residual recipient cells. Sensitivity
can be increased using lineage-speciﬁc analysis; however, this
method is usually inferior to disease-speciﬁc PCR method-
ologies and does not usually elucidate whether the residual
recipient cells are normal or malignant. In general, most
investigators wish to determine ﬁrst whether donor engraft-
ment has occurred and second whether there is mixed
chimerism. If mixed chimerism is present, it may be important
to know which lineages are mixed and which are fully donor.
With the recent introduction of nonmyeloablative condition-
ing regimens, it may be important to document both myeloid
and lymphoid chimerism. Both may be determined by periph-
eral blood analysis. Blood may be fractionated into speciﬁc lin-
eages by either positive or negative selection techniques. This
choice not only allows for analyses of individual lineages but
also increases the relative sensitivity of the technique.
For example, T cells may account for only 10% of
peripheral blood leukocytes and 3% of bone marrow cells
(a not uncommon ﬁnding following allogeneic transplanta-
tion). If the sensitivity of the method for determining
chimerism status is 1% and if 20% of the T cells are of
recipient origin and all other lineages are 100% donor, the
results shown in Table 2 would be obtained by chimerism
analyses of the listed samples. In this example, if the sensi-
tivity of the informative allele were limited to 3% detection
of recipient cells (a common observation using ﬂuorescent
primers), the analysis of the unfractionated peripheral blood
would have spuriously shown complete donor chimerism.
Therefore, the use of lineage-speciﬁc analyses will increase
the sensitivity of the method and allow for accurate assess-
ment of the myeloablative and immunoablative efficacy of
different conditioning regimens.
Little is known about mixed B-cell chimerism. It is
known to occur after transplantation for some varieties of
severe combined immunodeﬁciency if a myeloablative con-
ditioning regimen is not employed [21]. The presence of
mixed B-cell chimerism may be surmised by immunoglobu-
lin allotyping. Analysis using multicolor flow cytometry
for such antigens as CD132, (the common cytokine receptor
γ chain) or intracellular Wiscott-Aldrich syndrome protein
plus CD19 may be useful in future studies.
SUMMARY OF PRESENTATIONS
Assessment of Chimerism Following Myeloablative
Transplantation for Hematologic Malignancies
Most of the early studies of chimerism were done in
patients receiving myeloablative transplantation for hemato-
logic malignancies. Although mixed chimerism may be
detectable using sensitive techniques in some patients, most
patients undergoing unmanipulated transplantation will be
fully chimeric. Presumably, the T cells in the graft contribute
to the establishment of full donor chimerism by a graft-versus-
lymphohematopoiesis effect. In contrast, patients receiving
marrow that has been T-cell depleted by any of a number of
techniques are commonly found to have mixed chimerism
[22-25]. Thus, measurement of chimerism is not essential in
myeloablative transplantation using conventional conditioning
and GVHD prophylaxis. However, if the graft is manipulated,
new GVHD regimens are studied, or if the conditioning regi-
men is altered, the measurement of chimerism may be critical
to evaluate the effects of the new regimen.
Assessment of Chimerism Following
Nonmyeloablative Stem Cell Transplantation 
for Lymphoproliferative Disorders
In lymphoproliferative disorders, it is conceivable that a
GVL response that eradicates the malignancy does not need
to be associated with complete lymphohematopoietic
chimerism. Patients who are undertaking allogeneic cell
therapy after failed autologous transplantation or as part of a
tandem autologous/allogeneic program may be adequately
immunocompromised to allow engraftment without addi-
tional immunosuppression [26,27]. However, most patients
treated early in the course of their disease require additional
conditioning. Based on a preclinical murine model in which
mixed lymphohematopoietic chimerism is reliably induced
following nonmyeloablative preparative therapy and major
histocompatibility complex–mismatched bone marrow
transplantation [28], the group at Massachusetts General
Hospital developed a clinical protocol that incorporates
Table 2. Effect of Sample Type and Lineage Selection on Result of
Chimerism Analysis
Patient Sample Recipient T Cells, % Chimerism Result
Unseparated marrow 0.6 Donor
Unseparated blood 2 Mixed, lineage unknown
T cells 20 Mixed T cells
Granulocytes <1 Donor myeloid cells
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cyclophosphamide, peritransplantation equine antithymo-
cyte globulin or anti-CD2 monoclonal antibody (MEDI-507)
therapy, and pretransplantation thymic irradiation (in
patients who have not previously received mediastinal irra-
diation) as preparative therapy for HLA-matched and HLA-
mismatched bone marrow transplantation [29,30]. The goal
of this strategy was to induce mixed chimerism as an
immunological platform for cellular adoptive immuno-
therapy via donor leukocyte infusions (DLIs). DLIs in this
setting are intended to effect a powerful lymphohematopoi-
etic graft-versus-host reaction (with conversion of mixed
chimerism to full donor hematopoiesis) without causing
signiﬁcant GVHD.
Sixty-ﬁve patients have received an HLA matched (n = 43)
or mismatched (n = 22) bone marrow transplant following
this nonmyeloablative preparative regimen. Forty-four (68%)
of the 65 patients had a diagnosis of advanced non-Hodgkin’s
lymphoma. Most of these patients had chemotherapy-
refractory intermediate grade B–large cell non-Hodgkin’s
lymphoma, and most patients did not have bone marrow
involvement at the time of their transplantation.
Chimerism was measured by PCR analysis of VNTR or
STR sequence markers on weekly peripheral blood samples
from day 7 through day 100, then every 6 months, on day 28
and day 100, and on yearly bone marrow aspirate samples
[31,32]. In the majority of patients, CD3+ T-cell and CD3–
cell fractions were separated by an immunomagnetic cell
separation device. For recipients of HLA-mismatched donor
transplants, chimerisms of neutrophil, monocyte, and lym-
phocyte fractions were analyzed by flow cytometry using
allele-speciﬁc monoclonal anti-HLA antibodies [33].
Results of Chimerism Analyses
All patients initially achieved mixed chimerism. In
recipients of HLA-matched donor transplants, 3 patterns
of chimerism subsequently evolved (Figure 4). Following a
decline in the percentage of donor cells at or shortly after
engraftment (coincident with a clinical engraftment syn-
drome in most patients), the majority of patients achieved
persistent mixed chimerism or converted to full donor
hematopoiesis (either spontaneously or following “prophy-
lactic” DLI). Approximately 25% of patients ultimately
had graft loss.
The results of the chimerism studies correlated well
with the clinical sequelae of the transplantations, predicting
either risk of GVHD or graft loss (and lack of response to
DLI). Analysis of CD3+ T-cell chimerism at the time of
intended DLI (day 35 posttransplantation or later) demon-
strated that increasing levels of T-cell chimerism were asso-
ciated with GVHD, whereas T-cell levels of ≤20% were
associated with graft loss (despite prophylactic DLI in most
cases in which there was declining chimerism).
In recipients of HLA-mismatched donor transplants,
mixed chimerism as determined by VNTR/STR and flow
cytometric analysis was also initially achieved in all patients.
Approximately 85% of patients who received antithymocyte
globulin had sustained engraftment. Most of these patients
had spontaneous conversion to complete or nearly complete
Figure 4. The median percentage of donor cells found in the peripheral blood over time in 41 evaluable recipients of HLA-matched donor
hematopoietic stem cell transplantation. Three distinct patterns of chimerism have evolved: Full donor chimerism (FDC) developed either sponta-
neously or following donor leukocyte infusions (), sustained mixed chimerism (MC) (), and loss of donor chimerism (LDC) ().
J.H. Antin et al.
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donor chimerism (with GVHD). However, persistent mixed
chimerism was observed in the granulocyte and monocyte
lineages in several cases (Figure 5). Graft loss was seen in an
initial cohort of patients receiving an anti-CD2 monoclonal
antibody for in vivo T-cell depletion. Following adjustment
of the dose and timing of the anti-CD2 monoclonal anti-
body, sustained donor chimerism was observed in 2 of
3 evaluable patients. VNTR/STR analyses more reliably
predicted the clinical courses than flow cytometry; results
from the latter method showed spuriously high levels of
donor chimerism for several patients. In a comparison of the
percentage of donor cells in peripheral blood and bone mar-
row (at similar time points), no significant difference was
observed between the 2 sources of cells (data not shown).
Thus, mixed lymphohematopoietic chimerism can be
reliably induced following a nonmyeloablative preparative
regimen and HLA-matched– or HLA-mismatched–donor
bone marrow transplantation for lymphoproliferative disor-
ders. Prophylactic DLIs have been given to approximately
40% of patients with frequent conversion to full donor
hematopoiesis, often with striking antitumor responses.
Graft loss, however, has been a problem, particularly in the
HLA-matched–donor transplantation setting. In the experi-
ence of several other programs employing nonmyeloablative
preparative regimens for stem cell transplantation, chimerism
has been evaluated infrequently, and, in most situations, full
or nearly full donor hematopoiesis was established early
[34,35]. The use of DLIs was infrequent and given mostly
for persistent or progressive disease.
Chimerism Analysis After Nonmyeloablative and
Reduced-Intensity Conditioning for Myeloid
Leukemias
A determination of myeloid-speciﬁc chimerism is partic-
ularly important in patients with malignancies of myeloid
origin. Patients with myeloid leukemias in remission who
have persistently detectable recipient hematopoiesis, even at
extremely low levels, are at considerably higher risk for
relapse than those patients who have had a “graft-versus-
host hematopoietic effect” resulting in complete donor
myeloid chimerism. The assessment of myeloid chimerism,
in this setting, appears to offer a “surrogate” approach for
determining minimal residual disease, because any detectable
host myeloid cell populations would be suspected of harbor-
ing malignant cells capable of causing relapse.
Since 1994, the MD Anderson transplantation group
has been exploring both nonmyeloablative and reduced-
intensity conditioning regimens for allogeneic transplanta-
tion in patients with myeloid leukemia. The experience with
reduced-intensity conditioning and nonmyeloablative trans-
plantation has been obtained primarily in unsorted bone
marrow cells. Because bone marrow samples represent pri-
marily myeloid precursors, chimerism of unsorted bone
marrow cells is representative of myeloid lineage chimerism.
Chimerism analysis of unsorted bone marrow cells in
the setting of conventional ablative preparative regimen has
been reported to predict outcomes such as GVHD, graft
failure, and relapse. The results of chimerism analysis of
unsorted bone marrow cells for both nonmyeloablative and
reduced-intensity conditioning regimens are summarized in
Tables 3 and 4.
Figure 5. The pattern of mixed chimerism occurring in one patient (UPN 187) who was a recipient of an HLA-mismatched donor transplant
showing persistent mixed chimerism in the lymphoid (Lymphs), granulocyte (Polys), and monocyte (Monos) lineages.
Table 3. Chimerism Analysis of Unsorted Bone Marrow Cells in Patients
Undergoing Nonmyeloablative (FLAG-Ida) Conditioning Regimens*
Percentage Percentage
Donor Cells at Donor Cells at Primary/Secondary
Day 30 Day 360 Autologous
N (Range) (Range) Reconstitution
AML/MDS 27 95 (0-100) 100 (0-100) 4/2
CML-CP 7 100 (0-100) 100 (0-100) 1/2
CML-AP 6 45 (0-100) 0 3/6
*FLAG-Ida indicates ﬂudarabine, cytarabine, granulocyte colony–
stimulating factor, and idarubicin; AML, acute myelogenous leukemia;
MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia;
CP, chronic phase; AP, accelerated phase.
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Chimerism detected in unsorted bone marrow failed to
correlate with any clinical outcomes; however, this result
could be due to the small number of patients. However, as
seen in Table 5, there was no direct correlation between
unsorted bone marrow chimerism and T-cell chimerism.
These data demonstrate signiﬁcant interpatient differences
and the inability of unsorted samples to predict for T-cell
chimerism. Therefore, lineage-speciﬁc chimerism is essential
to better understanding of the biologic events that occur after
transplantation. In particular, lineage-specific chimerism
would allow exploration of the following hypotheses:
1. Lower levels of CD3+CD8+ donor-cell engraftment will
be more strongly associated with rejection than low lev-
els of donor CD3+CD4+ cells.
2. Low levels of CD34+CD38– donor cells will predict graft
failure or lack of long-term donor cell engraftment.
3. Mixed chimerism in myeloid lineages will predict
relapse in myeloid but not lymphoid malignancies.
4. Mixed chimerism in T-cell subsets will predict a lower
risk of acute GVHD.
Assessment of Chimerism After Transplantation for
Nonmalignant Disorders
A wide range of nonmalignant disorders are correctable
by hematopoietic stem cell transplantation, including
immunodeficiencies, acquired and congenital marrow fail-
ure syndromes, and hemoglobinopathies. Correction of
lethal and degenerative complications of certain systemic
metabolic disorders can also be achieved through stable
engraftment of hematopoietic cells with normal enzyme
activities. For many of these diseases, full hematopoietic
chimerism is not required to provide functional reversal or
“cure” of the underlying conditions. Thus, conditioning
protocols that are believed to be less myeloablative than
those containing total body irradiation are often used with
transplantation for treatment of such diseases. These regi-
mens are often adequate when treating disorders with
defects in lymphocyte function. In contrast, graft rejection
is a signiﬁcant problem in transplantation for treatment of
nonmalignant disorders in which immune and marrow
functions are robust and no prior chemotherapy has been
administered (eg, metabolic disorders), for which even fully
ablative conditioning may be inadequate to ensure durable
donor cell engraftment.
Long-term mixed chimerism is a frequent consequence
of transplantation for treatment of immunodeﬁciencies that
express pathologic lesions in the T-cell lineage, such as
severe combined immunodeficiencies (SCIDs), Wiskott-
Aldrich syndrome, and hemophagocytic lymphohistiocyto-
sis. Even with conventional “ablative” protocols (eg, busulfan,
cyclophosphamide, and etoposide), mixed chimerism in the
peripheral blood is seen in approximately 50% of cases.
After unrelated or alternative donor transplantation without
T-cell depletion, full donor chimerism may be somewhat
more common than it is after histocompatible sibling trans-
plantation, perhaps because of a stronger graft-versus-
hematopoiesis effect. In these disorders: (1) mixed chimerism
prior to day 100 does not predict rejection, (2) chimerism
can ﬂuctuate over time without speciﬁc interventions, and
(3) mixed chimerism is usually compatible with full correc-
tion of the T-cell dysfunction, because the circulating T cells
are completely, or predominantly, of donor type. Reversal of
Table 4. Chimerism Analysis of Unsorted Bone Marrow Cells in Patients Undergoing Reduced Intensity (Fludarabine/Melphalan) Conditioning Regimens
Mean Percentage Mean Percentage Failure/Secondary
of Donor Cells of Donor Cells Autologous
N at Day 30 at Day 360 Reconstitution, No.
Acute myelogenous leukemia/
myelodysplastic syndrome
Sibling 25 93.5 100 1/0
Unrelated donor 29 93.5 100 1/0
Chronic myelogenous leukemia
Sibling 16 1/1
Unrelated donor 18 2/1
Melphalan, 140 mg/m2
Yes 18 77.0 67 2/0
No 44 99.0 100 1/0
Antithymocyte globulin
Yes 10 75 66 2/10
No 51 96 100 1/51
Table 5. Results of Chimerism Analysis of Sorted and Unsorted Samples
Percentage Percentage
Patient Donor Cells Donor Cells
No. Cell Source (Unsorted) (T Cell)
13 Bone marrow 6 7
12 Bone marrow 11 12
3 Bone marrow 25 73
7 Bone marrow 30 63
11 Bone marrow 49 67
1 Bone marrow 62 72
9 Bone marrow 64 35
10 Bone marrow 75 0
15 Bone marrow 81 75
8 Bone marrow 85 89
8 Bone marrow 89 88
14 Bone marrow 96 95
4 Bone marrow 99 99
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proportional donor-type engraftment from 5% to 100% has
been observed. Generally speaking, engraftment of >10%
donor cells may be adequate for functional correction of the
underlying disease. An example of gradual increase in donor
chimerism (without specific intervention) is illustrated in
Figure 6, which represents the course of an 11-month-old
boy who received an unrelated-donor cord blood transplant
following conventional myeloablative chemotherapy for
Wiskott-Aldrich syndrome.
For congenital defects of nonlymphoid hematologic
lineages (eg, chronic granulomatous disease, leukocyte
adhesion deficiency, and sickle cell disease), sustained low
levels of donor-type hematopoiesis may suffice to reverse
the clinical consequences of the inborn errors, assuming
that some donor-type neutrophils or erythrocytes are con-
tinuously produced. Donor engraftment in the range of 3%
to 10% may be clinically useful.
In systemic metabolic disorders, such as Hurler’s syn-
drome or X-linked adrenoleukodystrophy, the consequences
of mixed hematopoietic chimerism are less well deﬁned. Early
recovery of host type cells after transplantation is often asso-
ciated with eventual complete graft rejection, whereas late
onset of mixed chimerism may have no discernible deleteri-
ous effect. There is growing evidence that stabilization of
neurologic disease depends on the earliest possible delivery of
adequate concentrations of corrective enzyme to the neural
tissues by circulating and tissue-specific donor-derived
hematopoietic cells. Thus, full hematopoietic chimerism fol-
lowing transplantation from a homozygous normal donor is
preferred. Figure 7 demonstrates successful reversal of declining
Figure 6. An 11-month-old patient with Wiskott-Aldrich syndrome received a 5/6 unrelated cord blood transplant. Initial mixed chimerism spon-
taneously converted to full donor chimerism over a year’s time, with concurrent recovery of normal platelet count.
Figure 7. A 2-year-old male patient received a 5/6-matched related donor hematopoietic stem cell transplant (HSCT) for Hurler’s syndrome. To
reverse declining donor engraftment, donor lymphocyte infusions (DLI) were administered 6.5 and 10 months post-HSCT, resulting in full donor
chimerism 10 months after marrow transplantation.
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donor type engraftment through the use of donor lymphocyte
infusions from the 5/6-matched related bone marrow donor
administered to a child with Hurler’s syndrome who had
received a myeloablative transplantation regimen.
Systemic disorders of chromosomal instability are due
to defects in cell cycle regulation or apoptosis (eg, Fanconi’s
anemia, Bloom’s syndrome, and autoimmune lymphoprolif-
erative disorders). These disorders predispose patients to
hematologic malignancies, therefore, full hematopoietic
engraftment is desirable.
Transplantation for aplastic anemia using a matched sib-
ling donor is usually undertaken with nonmyeloablative
conditioning regimens consisting of cyclophosphamide or
cyclophosphamide with antithymocyte globulin. Radiation-
based regimens are now primarily used in mismatched or
unrelated donor transplantation. There is a high likelihood
of encountering mixed chimerism after successful transplan-
tation for treatment of severe aplastic anemia using less
intense conditioning regimens. Indeed, occasional patients
may have complete recovery of host lymphohematopoiesis
[36,37]. At present, it is unknown whether the use of periph-
eral blood stem cells rather than bone marrow will affect the
overall incidence of mixed chimerism. Monitoring chimerism
after transplantation for aplastic anemia may be useful in the
assessment of graft loss and relapse, but as long as hemato-
poiesis is sustained, the presence of mixed chimerism may
not be clinically relevant.
A number of problems have been seen with persistent
mixed chimerism in nonmalignant disorders. These include:
(1) compartmental engraftment or split chimerism, eg, in
Wiskott-Aldrich syndrome, when donor lymphoid engraft-
ment exists, but defective host thrombopoiesis persists; (2)
alloimmunization—donor lymphocyte engraftment with
antibody-mediated antihost cytopenias; and (3) persistence
of host stem cells that have been exposed to potentially
transforming chemotherapies during the transplantation
procedure and eventually give rise to hematologic malignan-
cies. All of these complications represent transient or long-
term failures of the transplantation procedures.
Table 6 summarizes proportional chimerism deemed
adequate for long-term functional correction of nonmalig-
nant genetic diseases after HSCT. Evidence to date suggests
that the key factors that can favorably inﬂuence durable and
more complete donor-type engraftment in nonmalignant
genetic disorders include, in approximate descending order
of importance: larger graft cell dose, tolerable host/donor
histoincompatibility (without extensive T-cell depletion),
and intensity of conditioning regimen. Interventions after
the HSCT, such as early discontinuation of cyclosporine
prophylaxis and induction of GVHD, can sometimes lead to
establishment of donor cell predominance. With the current
interest in scaling back conditioning protocols for nonma-
lignant disorders, frequent testing for chimerism is required
to determine when immune suppression should be withdraw
and/or additional donor lymphocytes should be infused to
attempt to stabilize the declining donor graft.
Chimerism Assessment Following Nonmyeloablative
Hematopoietic Stem Cell Transplantation for Solid
Tumors
For the treatment of solid tumors, the preparative regi-
men often provides minimal to no direct antimalignancy
effect. Therefore, there is a greater need to rapidly establish
donor immune engraftment to a level sufﬁcient to confer a
graft-versus-tumor (GVT) effect. Chimerism assessment may
be used to successfully guide methods to manipulate donor
immune reconstitution to enhance a GVT effect (ie, modify-
ing posttransplantation immunosuppression and/or the infu-
sion of donor lymphocytes).
The rate and degree of donor engraftment following
HSCT may vary considerably between different cellular lin-
eages and are directly affected by factors such as the patient’s
pretransplantation immune status as well as the choice and
dose of agents used for conditioning and GVHD prophy-
laxis. The risk of graft rejection following HSCT in patients
with a prior history of autologous transplantation is low
[26,27]. Rather, such heavily immunosuppressed patients are
at risk for early and severe acute GVHD as a consequence of
rapid and complete donor immune engraftment. In contrast,
patients with little to no history of prior chemotherapy (ie,
solid tumor patients, chronic myeloid leukemia patients)
undergoing HSCT frequently have more delayed donor
engraftment and appear to be at higher risk for graft rejec-
tion than patients who have received multiple prior
chemotherapeutic regimens.
The critical impact that different conditioning agents
have on donor engraftment has become increasingly clear
over the past few years. For instance, regimens that use
Table 6. Donor Chimerism Levels Desirable for Functional Correction of Genetic Disorders*
Percentage Donor Cells† Diseases Comments
3-10 Sickle cell anemia RBC graft required
Chronic granulomatous disease PMN graft required
Leukocyte adhesion deficiency PMN, lymphoid graft required
>10 Severe combined immunodeficiency Usually T cells‡
Wiskott-Aldrich syndrome Platelet graft required
CD40 ligand deficiency
Hemophagocytic lymphohistiocytosis NK-cell, CTL graft required
100 Autoimmune lymphoproliferative syndrome
Fanconi’s anemia
*RBC indicates red blood cells; PMN, polymorphonucleocytes; NK, natural killer; CTL, cytotoxic T lymphocyte.
†Peripheral blood nucleated cells.
‡Many patients require lifetime intravenous immunoglobulin G because of lack of B-cell engraftment.
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“stem-cell toxic” agents such as melphalan, even at lower
doses, are still highly myelosuppressive and are much less
likely to permit the high levels of autologous myeloid recov-
ery that are seen with regimens that spare recipient stem
cells. In contrast, regimens that use less myelosuppressive
(non–stem-cell toxic) but more immunosuppressive agents
such as cyclophosphamide and ﬂudarabine are much more
likely to result in lower degrees of early donor myeloid
engraftment, largely as a consequence of the substantial
autologous hematopoietic recovery that ensues. In studies
performed at the National Institutes of Health, a cyclophos-
phamide (120 mg/kg)/ﬂudarabine (125 mg/m2)-based condi-
tioning regimen followed by infusion of a T-cell replete
allograft resulted in considerably higher levels of early
donor T-cell engraftment than occurred in donor myeloid
lineages [38,39]. Indeed, the observation that full donor
T-cell chimerism occurred more promptly than full donor
myeloid chimerism in the majority of patients receiving
such conditioning provides evidence that cyclophosphamide
and fludarabine, given in combination at these doses, are
more immunosuppressive than myelosuppressive. Further-
more, when this cyclophosphamide/ﬂudarabine-based non-
myeloablative transplantation protocol was modified to
include a T-cell–depleted allograft, the degree of early donor
T-cell engraftment declined substantially and was associated
with a higher incidence of graft rejection. These observa-
tions highlight the critical role that allogeneic lymphocytes
play in facilitating donor engraftment following nonmye-
loablative HSCT. Furthermore, the observation that low
degrees of early donor T-cell engraftment are associated with
a higher incidence of graft rejection and a decreased proba-
bility of both GVHD and the generation of a GVT effect
emphasizes the importance of assessing lineage-specific
chimerism for prognostic reasons as well as to permit suc-
cessful posttransplantation engraftment manipulation.
Whereas most patients with hematological malignan-
cies receive multiple rounds of highly immunosuppressive
chemotherapy prior to undergoing allogeneic transplanta-
tion, many patients with solid tumors are chemotherapy
naive prior to undergoing HSCT. In patients with solid
tumors, T-cell chimerism predicted for major alloimmune
responses, including the risk of acute GVHD, graft rejec-
tion, and the generation of a GVT effect. Patients with
high degrees of early donor T-cell chimerism (Figure 8)
were significantly more likely to develop acute GVHD
than those with lower degrees of early donor T-cell
engraftment. Furthermore, acute GVHD typically was not
observed until T-cell chimerism had become predomi-
nantly donor in origin or during the period when T-cell
chimerism was in transition from mixed toward complete
donor. Graft rejection occurred in less than 5% of patients
and was seen only in patients who had low degrees of early
donor T-cell engraftment (typically <50% donor). The
onset of a GVT effect was similar to the onset of GVHD,
particularly in patients with renal cell carcinoma, in whom
the response was often markedly delayed and did not
occur until T-cell chimerism was completely donor or was
in transition from mixed to complete donor in origin (Fig-
ure 9). The assessment of T-cell chimerism, therefore,
provides important prognostic information and should be
analyzed in this setting.
The optimal methodology to assess chimerism follow-
ing such procedures is currently uncertain. In solid tumor
transplantation there have been no signiﬁcant differences in
myeloid or T-cell chimerism in cellular fractions isolated
from the either the peripheral blood or bone marrow. Kary-
otyping of unsorted bone marrow metaphases in sex-
mismatched transplantation has not been useful to assess
donor engraftment, because the majority of such metaphase
cells are myeloid in origin, providing little insight into the
T-cell compartment. In several instances, day 30 bone mar-
row analysis revealed no evidence for donor-type sex chro-
mosomes in routine metaphase spreads at a time when
lineage-specific chimerism (analyzed by VNTR analysis)
Figure 8. Percentage of patients on day 30 with <90% donor T-cell chimerism or ≥ 90% donor T-cell chimerism. Patients with more rapid (ie, ≥ 90%)
donor T-cell engraftment by day 30 were at higher risk for developing acute grade II to IV graft-versus-host disease (GVHD) (68% actuarial risk)
than those with more delayed donor T-cell engraftment (17% actuarial risk), shown in black. RR indicates relative risk; CI, conﬁdence interval.
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revealed T cells that were substantially donor in origin.
Karyotypic assessment of donor engraftment alone could
lead to a false diagnosis of graft rejection, especially with
regimens associated with high degrees of autologous
myeloid recovery. Hypermetaphase FISH analysis is
unlikely to be more helpful in this setting.
RECOMMENDATIONS
1. Chimerism analysis should be undertaken using sensi-
tive (<1%), informative techniques. At present,
STR/VNTR analysis is the approach most likely to
give reproducible informative data. Cytogenetics,
FISH, and hypermetaphase FISH may also be useful if
STR/VNTR is unavailable or in sex-mismatched trans-
plantation. However, these techniques are less sensitive.
Analyses used for clinical decision-making should be
performed in Clinical Laboratory Improvement Amend-
ment (CLIA)-certiﬁed laboratories.
2. Peripheral blood stem cells are generally more useful than
bone marrow cells for chimerism analysis. Chimerism of
unsorted bone marrow cells allows for documentation of
origin of myeloid cells; however, it correlates poorly with
chimerism of T cells and cells of other lineages and pro-
vides little information about degree of chimerism in
other cellular subsets. Lineage-speciﬁc chimerism should
be considered the assay of choice in the setting of non-
myeloablative and reduced-intensity conditioning.
3. Chimerism analysis after myeloablative HSCT using
conventional GVHD prophylaxis is probably not essen-
tial and can be considered optional. If it is obtained, a
schedule of 1, 3, 6, and 12 months is reasonable. Once
full chimerism is established, repeat testing is unneces-
sary unless there is a change in clinical condition. The
use of T-cell depletion, nonmyeloablative or reduced-
intensity conditioning, or novel GVHD prophylactic
regimens warrants chimerism analysis at 1, 3, 6, and
12 months, because interventions such as donor lym-
phocyte infusions may depend on donor status.
a. Patients undergoing transplantation for treatment
of aplastic anemia should have routine chimerism
analysis done on unfractionated blood specimens at
1, 3, 6, and 12 months. Additional testing may be
warranted if clinically indicated.
4. In nonmyeloablative transplantation, the early patterns
of chimerism may be predictive for either GVHD
(increasing donor T-cell chimerism) or graft loss (declin-
ing donor T-cell chimerism to ≤20% donor cells).
Therefore, if therapeutic intervention is based on these
patterns of chimerism, the following recommendations
apply to protocols in which achieving mixed chimerism
as an immunological platform for DLI is a primary goal:
a. Frequent (every 2-4 weeks) peripheral blood analy-
sis of chimerism by VNTR or STR analysis until
DLI is administered. DLIs are then considered for
declining chimerism (but T-cell chimerism greater
Figure 9. Relationship of donor T-cell and myeloid chimerism to clinical events in a patient with metastatic renal cell carcinoma (RCC) undergo-
ing nonmyeloablative allogeneic peripheral blood stem cell transplantation. High degrees of recipient myeloid and donor T-cell chimerism observed
in the ﬁrst 2 months following transplantation result as a consequence of using nonmyeloablative conditioning, which is more immunosuppressive
than myelosuppressive conditioning (ﬂudarabine and cyclophosphamide). Conversion from mixed to complete donor chimerism is achieved follow-
ing the withdrawal of cyclosporine (CSA) and a donor lymphocyte infusion (DLI) of 1 × 107 CD3+ cells/kg, consistent with a graft-versus-host lym-
phohematopoietic effect. Acute graft-versus-host disease (GVHD) and RCC disease regression were associated with the transition from mixed to
complete donor chimerism compatible with a break in donor tolerance to host antigens.
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than 20%), stable mixed chimerism of >2 weeks
duration, or persistent/progressive disease.
b. For patients who have developed GVHD and are
not DLI candidates or who have achieved full donor
chimerism, infrequent chimerism analyses are rec-
ommended (every 3-6 months).
c. Multiple chimerism evaluations (initially every
2-4 weeks, then every 3-6 months) are recommended
following prophylactic DLI, both to evaluate the
effect on chimerism of the DLI and to discern
whether additional DLIs are necessary.
5. For nonmalignant disorders other than aplastic anemia,
chimerism analysis should generally be done at 1, 2, and
3 months posttransplantation.
a. If the proportion of donor cells is observed to
decline, ongoing monthly follow-up is warranted.
Interventions to enhance donor engraftment must be
considered on a disease-speciﬁc basis and related to
concurrent GVHD and, ultimately, clinical rationale.
b. In some diseases, definition of donor engraftment
by hematopoietic lineage is useful in interpreting
the transplantation outcomes. Lineage-speciﬁc ﬂow-
cytometric sorting or other cell-type sorting can be
used. For certain immunodeﬁciencies, ﬂow cytome-
try can be used to detect donor-derived lymphoid
subsets by the presence of expressed cell surface
molecules specifically deficient in a given disease,
eg, CD132 in X-linked SCID or CD127 in inter-
leukin-7R α–deﬁcient SCID.
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